MorphoSys
German biopharmaceutical company focused on antibody-based drug discovery and development.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
MorphoSys AG was a German biopharmaceutical company established in 1992 and headquartered in Planegg near Munich. Its business was built around the discovery, engineering and development of antibody-based medicines, supported by proprietary platforms for human antibody generation, optimization and the creation of more complex biologic formats. The company worked both as a technology and drug-discovery partner for large pharmaceutical companies and as a developer of its own therapeutic pipeline. MorphoSys became particularly associated with HuCAL, or Human Combinatorial Antibody Library, a large phage-display library of fully human antibodies. The platform was designed to support the rapid identification and optimization of antibodies against disease-related targets. Over time, MorphoSys expanded its technology portfolio to include additional antibody-engineering capabilities, including the OkapY format for developing so-called 2+1 bispecific antibodies. These technologies enabled collaborations and licensing arrangements with pharmaceutical companies including Bayer, Roche, Centocor, Schering, Pfizer and Novartis. The company listed on the Frankfurt Stock Exchange in 1999 and later expanded its access to United States capital markets through a Nasdaq initial public offering in 2018. Its corporate structure included MorphoSys US Inc., a wholly owned subsidiary established in 2018 and based in Boston. Although the company maintained a broad partnered and proprietary pipeline, its strategic emphasis increasingly moved toward oncology and later-stage development programs. In 2023, MorphoSys announced that it would discontinue preclinical research activities and concentrate resources on mid- to late-stage oncology assets in response to pressures in the pharmaceutical market and the need to optimize costs. MorphoSys's most important commercial milestone was guselkumab, an antibody discovered using its technology and subsequently developed and commercialized by Janssen Biotech, a Johnson & Johnson company, under the brand name Tremfya. The medicine received its first United States approval in 2017 for moderate-to-severe plaque psoriasis and was also approved in the European Union and Canada. MorphoSys itself later advanced tafasitamab, an anti-CD19 antibody also known as MOR208, in partnership with Incyte. The product was approved by the U.S. Food and Drug Administration in 2020 as Monjuvi, in combination with lenalidomide, for certain adults with relapsed or refractory diffuse large B-cell lymphoma who were not eligible for autologous stem-cell transplantation. Other important programs included otilimab, an anti-GM-CSF antibody licensed to GlaxoSmithKline, and felzartamab, an anti-CD38 antibody investigated in autoimmune and hematologic indications. In 2021, MorphoSys acquired Constellation Pharmaceuticals for approximately US$1.7 billion, strengthening its oncology portfolio and adding epigenetic drug programs. In February 2024, Novartis agreed to acquire MorphoSys for approximately €2.7 billion. MorphoSys subsequently announced plans to delist from the Frankfurt Stock Exchange and merge into Novartis. The merger received shareholder approval in August 2024, ending MorphoSys's existence as an independent publicly traded company.
History
MorphoSys was founded in Germany in 1992 as a biotechnology company centered on antibody discovery. Its early identity was shaped by the development of proprietary tools intended to make the identification of therapeutic antibodies faster and more systematic. The central platform was HuCAL, a large human combinatorial antibody library based on phage display. By using libraries of fully human antibodies and methods for selecting and optimizing candidates, the company sought to provide drug-discovery capabilities to both internal programs and external pharmaceutical partners. The company formed a series of partnerships during its early expansion. Discovery relationships were established with Bayer in 1999, Roche in 2000, Centocor, now part of Janssen Biotech, in 2000, Schering in 2001 and Pfizer in 2003. MorphoSys also entered a strategic research and development relationship with Novartis in 2004, which was expanded in 2007. These agreements gave the company access to larger development and commercialization networks while allowing partners to use its antibody technologies in the search for medicines. MorphoSys became a publicly traded company on the Frankfurt Stock Exchange in 1999. It later broadened its investor base through a U.S. initial public offering in 2018, after which its American depositary shares traded on Nasdaq. In the same year, the company established MorphoSys US Inc. in Boston, creating a dedicated U.S. corporate presence close to the country's biotechnology and pharmaceutical ecosystem. The company's technology generated important partnered products. Guselkumab, an antibody discovered using MorphoSys's platform, was developed and commercialized by Janssen Biotech under the Tremfya brand. Its first U.S. approval came in 2017 for moderate-to-severe plaque psoriasis, followed by approvals in other major markets. The achievement demonstrated that MorphoSys's platform could contribute to medicines that reached commercial markets even when the company was not the ultimate commercial owner. MorphoSys also advanced proprietary and co-developed medicines. MOR103, later known as otilimab or GSK3196165, entered clinical development in 2008 as a fully human antibody directed against granulocyte-macrophage colony-stimulating factor. After encouraging rheumatoid-arthritis results, MorphoSys licensed the program to GlaxoSmithKline, which later initiated a Phase 3 program. MOR208, later named tafasitamab, was a humanized anti-CD19 antibody. MorphoSys licensed technology related to the program from Xencor in 2010 and subsequently developed tafasitamab for B-cell malignancies. Tafasitamab became a defining corporate milestone. MorphoSys and Incyte signed a global development and commercialization agreement in January 2020, which became effective after antitrust clearance. In July 2020, the FDA approved tafasitamab-cxix as Monjuvi, in combination with lenalidomide, for specified adults with relapsed or refractory diffuse large B-cell lymphoma who were not eligible for autologous stem-cell transplantation. The approval gave MorphoSys a marketed medicine associated with its own development strategy while retaining a major commercial partnership. The company broadened its oncology ambitions through the 2021 acquisition of Constellation Pharmaceuticals for approximately US$1.7 billion. The transaction added clinical-stage programs and strengthened MorphoSys's focus on cancer biology. At the same time, the company continued to maintain a wider pipeline of partnered and proprietary antibodies directed at oncology, autoimmune and other diseases. Felzartamab, an anti-CD38 antibody, was investigated in hematologic and autoimmune indications, including anti-PLA2R-positive membranous nephropathy, and was licensed for development and commercialization in Greater China to I-Mab. In March 2023, MorphoSys announced a major change in operating strategy. It ended preclinical research programs and related activities, citing difficult pharmaceutical-market conditions and the need to optimize its cost base. Resources were redirected to mid- and late-stage oncology assets. This represented a move away from maintaining a broad early research engine and toward concentrating capital on programs with nearer-term development potential. In February 2024, Novartis agreed to acquire MorphoSys for approximately €2.7 billion. MorphoSys later announced plans to delist from the Frankfurt Stock Exchange and merge into Novartis. Shareholder approval in August 2024 marked the completion of the merger process described in the available reference material. MorphoSys therefore ceased to operate as an independent publicly traded biopharmaceutical company, with its assets and programs becoming part of Novartis.
- 2024
Novartis acquisition and merger
[1]Novartis agrees to acquire MorphoSys, and the merger is approved in August after the company announces plans to delist from Frankfurt.
- 2023
Preclinical research is discontinued
[1]MorphoSys ends preclinical research activities and concentrates resources on mid- and late-stage oncology programs.
- 2021
Constellation Pharmaceuticals acquisition
[1]MorphoSys acquires clinical-stage biotechnology company Constellation Pharmaceuticals for approximately US$1.7 billion.
- 2020
Monjuvi receives FDA approval
[1]Tafasitamab-cxix is approved in the United States as Monjuvi for specified adults with relapsed or refractory diffuse large B-cell lymphoma.
- 2018
Nasdaq offering and U.S. subsidiary
[1]MorphoSys completes a U.S. initial public offering and establishes MorphoSys US Inc. in Boston.
- 2017
Guselkumab receives first approval
[1]Guselkumab, commercialized by Janssen as Tremfya, receives U.S. approval for moderate-to-severe plaque psoriasis.
- 2010
MOR208 program expands through Xencor license
[1]MorphoSys signs a license agreement with Xencor for MOR208, later known as tafasitamab.
- 2008
MOR103 enters clinical development
[1]The company's first proprietary antibody program, MOR103, later called otilimab, enters clinical development.
- 2004
Novartis strategic partnership begins
[1]MorphoSys and Novartis enter a strategic partnership for biopharmaceutical research and development.
- 1999
Frankfurt Stock Exchange listing
[1]MorphoSys lists on the Frankfurt Stock Exchange under the ticker MOR.
Products and positioning
A science-led biopharmaceutical developer and antibody-platform company combining partnered discovery work with proprietary development, particularly in oncology and autoimmune disease.
Antibody discovery platform
HuCAL
HuCAL, short for Human Combinatorial Antibody Library, was MorphoSys's principal antibody-discovery technology. It used a large phage-display library of fully human antibodies together with selection and optimization methods to identify molecules against biological targets. The platform supported MorphoSys's internal pipeline and numerous collaborations with pharmaceutical companies, helping establish the company as a technology-enabled partner in biologic drug discovery.
Oncology monoclonal antibody · 2020
Tafasitamab
Tafasitamab, formerly MOR208, is a humanized monoclonal antibody directed against CD19, a target expressed on many B cells. It was developed for B-cell malignancies and evaluated in combination with other anticancer treatments. In the United States, tafasitamab-cxix was approved as Monjuvi in combination with lenalidomide for specified adults with relapsed or refractory diffuse large B-cell lymphoma who were not eligible for autologous stem-cell transplantation.
Immunology monoclonal antibody · 2017
Guselkumab
Guselkumab is an antibody discovered using MorphoSys technology and subsequently developed and commercialized by Janssen Biotech under the Tremfya brand. It targets the interleukin-23 pathway and was first approved in the United States in 2017 for moderate-to-severe plaque psoriasis. The product was also approved in the European Union and Canada, making it a major example of a MorphoSys-originated antibody reaching global commercialization through a pharmaceutical partner.
Autoimmune-disease monoclonal antibody · 2008
Otilimab
Otilimab, initially designated MOR103 and later GSK3196165, is a fully human monoclonal antibody directed against granulocyte-macrophage colony-stimulating factor. MorphoSys advanced the program into clinical development for inflammatory diseases, including rheumatoid arthritis, and later licensed it to GlaxoSmithKline. GSK initiated a Phase 3 rheumatoid-arthritis development program in 2019.
Hematology and autoimmune monoclonal antibody
Felzartamab
Felzartamab, also known as MOR202, is a humanized monoclonal antibody directed against CD38. It was investigated in hematologic diseases and in autoimmune conditions, including anti-PLA2R-positive membranous nephropathy. MorphoSys entered a regional licensing agreement with I-Mab for development and commercialization in Greater China, where the program was also known as TJ202.
Bispecific antibody technology
OkapY
OkapY is MorphoSys's proprietary 2+1 bispecific antibody format. The technology was designed to support molecules that engage more than one biological target or binding site while retaining physicochemical characteristics intended to facilitate development and large-scale manufacturing.
Brand decisions
2024
Accept Novartis acquisition and mergerM&ABackground
Novartis agreed to acquire MorphoSys for approximately €2.7 billion, followed by a proposed delisting and merger.
Action taken
MorphoSys announced plans to delist from the Frankfurt Stock Exchange and merge into Novartis; shareholders approved the merger in August 2024.
Aftermath
MorphoSys ceased to exist as an independent publicly traded company and became part of Novartis.
Agreed acquisition value. Approximately €2.7 billion (Announced February 2024)
2023
Concentrate resources on later-stage oncologyStrategyBackground
MorphoSys cited difficult conditions in the pharmaceutical market and the need to improve its cost structure.
Action taken
The company ended its preclinical research programs and related activities, redirecting resources toward mid- and late-stage oncology products.
Aftermath
The decision narrowed MorphoSys's research scope and emphasized development programs considered closer to potential commercialization.
Recent events
- 2024
MorphoSys and Novartis agree on acquisition[1]
M&A
Novartis agreed to acquire MorphoSys for approximately €2.7 billion, subject to the required corporate and regulatory steps.
- 2024
MorphoSys announces planned delisting and merger into Novartis[1]
M&A
The company announced its intention to leave the Frankfurt Stock Exchange and merge into Novartis after completion of the acquisition process.
- 2024
MorphoSys shareholders approve merger[1]
M&A
The proposed merger with Novartis received approval in August 2024, completing the principal corporate step toward integration.
- 2023
MorphoSys ends preclinical research programs[1]
Other
MorphoSys discontinued its preclinical research activities and redirected resources toward mid- and late-stage oncology programs while seeking to improve its cost structure.
- 2021
MorphoSys acquires Constellation Pharmaceuticals[1]
M&A
MorphoSys announced the acquisition of clinical-stage biotechnology company Constellation Pharmaceuticals for approximately US$1.7 billion.
- 2020
FDA approves Monjuvi for relapsed or refractory diffuse large B-cell lymphoma[1]
Product launch · Product generation
The FDA approved tafasitamab-cxix, sold as Monjuvi, in combination with lenalidomide for specified adults with relapsed or refractory diffuse large B-cell lymphoma.
- 2020
MorphoSys and Incyte establish global tafasitamab collaboration[1]
M&A · Other
MorphoSys and Incyte entered a collaboration and license agreement covering the global development and commercialization of tafasitamab; the agreement became effective after antitrust clearance.
- 2018
MorphoSys launches Nasdaq public offering[1]
Other
Following a U.S. initial public offering, American depositary shares of MorphoSys began trading on Nasdaq under the symbol MOR.
- 2017
Guselkumab receives first marketing approval[1]
Product launch
Guselkumab, discovered using MorphoSys technology and commercialized by Janssen as Tremfya, received its first U.S. approval for moderate-to-severe plaque psoriasis.
- 2007
MorphoSys and Novartis expand strategic research partnership[1]
Other
The strategic relationship established with Novartis in 2004 was expanded to cover additional research and development activities.
Sources7 sources
- 1MorphoSysen.wikipedia.org
- 2FDA Approves Monjuvi (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)finanznachrichten.de
- 3MorphoSys AG Reports Third Quarter 2019 Financial Resultsfinanznachrichten.de
- 4MorphoSys AG: MorphoSys Appoints Sung Lee as Chief Financial Officerfinanznachrichten.de
- 5MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticalsfinance.yahoo.com
- 6MorphoSys Appoints Sung Lee As CFOfinanznachrichten.de
- 7MorphoSys Appoints Sung Lee as Chief Financial Officerbiospace.com
Cite this profile: Cite the canonical profile. /brand-wiki/morphosys · Editorial policy · How profiles are compiled